Abstract
Inflammatory bowel diseases are commonly first diagnosed in the second and third decades of life and typically require lifelong treatment, which overlaps with the childbearing years. Inflammatory bowel disease (IBD) leads to an increased risk for pregnancy complications and adverse pregnancy outcomes, but having active disease at the time of conception and/or during pregnancy further increases this risk. Preconception counseling about the importance of obtaining disease remission at least 3 months prior to conception as well as the importance of adherence to the appropriate medical treatment in order to maintain remission during pregnancy is paramount to optimizing pregnancy and neonatal outcomes. This chapter will provide the most recent evidence regarding the safety of the currently available biologic medications, including anti-TNFα inhibitors, anti-integrin medications, and anti-IL-12/IL-23 agents, during pregnancy and with breastfeeding.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
